nach oben

DGNeurologie

Erschienen in:

09.05.2023 | Apoplex | CME Zertifizierte Fortbildung

Update zu Diagnostik und Therapie der Moyamoya-Angiopathie

Ein White Paper anlässlich der ersten europäischen Leitlinien 2023

verfasst von: Prof. Dr. med. M. Krämer, P. Vajkoczy, N. Khan

Erschienen in: DGNeurologie | Ausgabe 3/2023

zum CME-Kurs Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Moyamoya-Angiopathie ist eine sehr seltene intrakraniale nicht-entzündliche Vasopathie, die durch Stenosen und Verschlüsse der intrakranialen Abschnitte der Aa. carotides internae, cerebri mediae und anteriores gekennzeichnet ist. Namensgebend ist das kompensatorische Kollateralnetz. Während die Erkrankung in Japan, Korea und China bekannter ist, ist in Europa eine hohe Fehldiagnoserate beschrieben, und es wird von einer höheren Dunkelziffer ausgegangen. Klinische Manifestationen sind hämodynamische sowie embolische zerebrale Ischämien, oft auch wiederholte getriggerte transitorisch ischämische Attacken, zerebrale Blutungen, Kopfschmerzen, Bewegungsstörungen und kognitive Defizite. Eine frühe Detektion sowie eine fundierte Indikationsstellung einer zielführenden Therapie, ob konservativ oder mittels Bypass-Operation, erscheint bei dem hohen Risiko von Behinderung bis hin zu tödlichen Komplikationen wichtig.

Suzuki J, Takaku A (1969) Cerebrovascular “moyamoya” disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol 20(3):288–299CrossRefPubMed

Ihara M, Yamamoto Y, Hattori Y, Liu W, Kobayashi H, Ishiyama H, Yoshimoto T, Miyawaki S, Clausen T, Bang OY, Steinberg GK, Tournier-Lasserve E, Koizumi A (2022) Moyamoya disease: diagnosis and interventions. Lancet Neurol 21(8):747–758. https://doi.org/10.1016/S1474-4422(22)00165-XCrossRefPubMed

Kuroda S, Fujimura M, Takahashi J, Kataoka H, Ogasawara K, Iwama T, Tominaga T, Miyamoto S, Research Committee on Moyamoya Disease of the Ministry of Health L, Welfare J (2022) Diagnostic criteria for Moyamoya disease—2021 revised version. Neurol Med Chir 62(7):307–312. https://doi.org/10.2176/jns-nmc.2022-0072CrossRef

Hackenberg A, Battilana B, Hebeisen M, Steinfeld R, Khan N (2021) Preoperative clinical symptomatology and stroke burden in pediatric moyamoya angiopathy: Defining associated risk variables. Eur J Paediatr Neurol 35:130–136. https://doi.org/10.1016/j.ejpn.2021.10.007CrossRefPubMed

Acker G, Goerdes S, Schneider UC, Schmiedek P, Czabanka M, Vajkoczy P (2015) Distinct clinical and radiographic characteristics of moyamoya disease amongst European Caucasians. Eur J Neurol 22(6):1012–1017. https://doi.org/10.1111/ene.12702CrossRefPubMed

Kraemer M, Schwitalla JC, Diesner F, Aktas O, Hartung HP, Berlit P (2019) Clinical presentation of Moyamoya angiopathy in Europeans: experiences from Germany with 200 patients. J Neurol 266(6):1421–1428. https://doi.org/10.1007/s00415-019-09277-1CrossRefPubMed

Kim JS (2016) Moyamoya disease: epidemiology, clinical features, and diagnosis. J Stroke 18(1):2–11. https://doi.org/10.5853/jos.2015.01627CrossRefPubMedPubMedCentral

Zhang D, Huang L, Huang Z, Zhou Q, Yang X, Gu H, Li Z, Shi Y, Gan L, Wang H, Ma X, Wang Y, Zhao J (2022) Epidemiology of Moyamoya disease in China: a nationwide hospital-based study. Lancet Reg Health West Pac 18:100331. https://doi.org/10.1016/j.lanwpc.2021.100331CrossRefPubMed

Baba T, Houkin K, Kuroda S (2008) Novel epidemiological features of moyamoya disease. J Neurol Neurosurg Psychiatry 79(8):900–904. https://doi.org/10.1136/jnnp.2007.130666CrossRefPubMed

10.

Khan N, Yonekawa Y (2008) Moyamoya angiopathy in Europe: the beginnings in Zurich, practical lessons learned, increasing awareness and future perspectives. Acta Neurochir Suppl 103:127–130. https://doi.org/10.1007/978-3-211-76589-0_23CrossRefPubMed

11.

Uchino K, Johnston SC, Becker KJ, Tirschwell DL (2005) Moyamoya disease in Washington State and California. Neurology 65(6):956–958. https://doi.org/10.1212/01.wnl.0000176066.33797.82CrossRefPubMed

12.

Birkeland P, Lauritsen J (2018) Incidence of Moyamoya disease in Denmark: a population-based register study. Acta Neurochir Suppl 129:91–93. https://doi.org/10.1007/978-3-319-73739-3_13CrossRefPubMed

13.

Kuroda S, Group AS (2015) Asymptomatic moyamoya disease: literature review and ongoing AMORE study. Neurol Med Chir 55(3):194–198. https://doi.org/10.2176/nmc.ra.2014-0305CrossRef

14.

Graf J, Schwitalla JC, Albrecht P, Veltkamp R, Berlit P, Hartung HP, Aktas O, Kraemer M (2019) Misdiagnoses and delay of diagnoses in Moyamoya angiopathy—a large Caucasian case series. J Neurol. https://doi.org/10.1007/s00415-019-09245-9CrossRefPubMed

15.

Houkin K, Ito M, Sugiyama T, Shichinohe H, Nakayama N, Kazumata K, Kuroda S (2012) Review of past research and current concepts on the etiology of moyamoya disease. Neurol Med Chir 52(5):267–277CrossRef

16.

Mertens R, Graupera M, Gerhardt H, Bersano A, Tournier-Lasserve E, Mensah MA, Mundlos S, Vajkoczy P (2022) The genetic basis of Moyamoya disease. Transl Stroke Res 13(1):25–45. https://doi.org/10.1007/s12975-021-00940-2CrossRefPubMed

17.

Weinberg DG, Arnaout OM, Rahme RJ, Aoun SG, Batjer HH, Bendok BR (2011) Moyamoya disease: a review of histopathology, biochemistry, and genetics. Neurosurg Focus 30(6):E20. https://doi.org/10.3171/2011.3.FOCUS1151CrossRefPubMed

18.

Kraemer M, Keyvani K, Berlit P, Diesner F, Marquardt M (2019) Histopathology of Moyamoya angiopathy in a European patient. J Neurol 266(9):2258–2262. https://doi.org/10.1007/s00415-019-09406-wCrossRefPubMed

19.

Liu W, Morito D, Takashima S, Mineharu Y, Kobayashi H, Hitomi T, Hashikata H, Matsuura N, Yamazaki S, Toyoda A, Kikuta K, Takagi Y, Harada KH, Fujiyama A, Herzig R, Krischek B, Zou L, Kim JE, Kitakaze M, Miyamoto S, Nagata K, Hashimoto N, Koizumi A (2011) Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. Plos One 6(7):e22542. https://doi.org/10.1371/journal.pone.0022542CrossRefPubMedPubMedCentral

20.

Liu W, Hitomi T, Kobayashi H, Harada KH, Koizumi A (2012) Distribution of moyamoya disease susceptibility polymorphism p.R4810K in RNF213 in East and Southeast Asian populations. Neurol Med Chir 52(5):299–303. https://doi.org/10.2176/nmc.52.299CrossRef

21.

Liao X, Deng J, Dai W, Zhang T, Yan J (2017) Rare variants of RNF213 and moyamoya/non-moyamoya intracranial artery stenosis/occlusion disease risk: a meta-analysis and systematic review. Environ Health Prev Med 22(1):75. https://doi.org/10.1186/s12199-017-0680-1CrossRefPubMedPubMedCentral

22.

Liu W, Senevirathna ST, Hitomi T, Kobayashi H, Roder C, Herzig R, Kraemer M, Voormolen MH, Cahova P, Krischek B, Koizumi A (2013) Genomewide association study identifies no major founder variant in Caucasian moyamoya disease. J Genet 92(3):605–609. https://doi.org/10.1007/s12041-013-0304-5CrossRefPubMed

23.

Guey S, Kraemer M, Herve D, Ludwig T, Kossorotoff M, Bergametti F, Schwitalla JC, Choi S, Broseus L, Callebaut I, Genin E, Tournier-Lasserve E, consortium F (2017) Rare RNF213 variants in the C-terminal region encompassing the RING-finger domain are associated with moyamoya angiopathy in Caucasians. Eur J Hum Genet 25(8):995–1003. https://doi.org/10.1038/ejhg.2017.92CrossRefPubMedPubMedCentral

24.

Hirano Y, Miyawaki S, Imai H, Hongo H, Ohara K, Dofuku S, Teranishi Y, Nakatomi H, Saito N (2020) Association between the onset pattern of adult Moyamoya disease and risk factors for stroke. Stroke 51(10):3124–3128. https://doi.org/10.1161/STROKEAHA.120.030653CrossRefPubMed

25.

Kim DY, Son JP, Yeon JY, Kim GM, Kim JS, Hong SC, Bang OY (2017) Infarct pattern and collateral status in adult Moyamoya disease: a multimodal magnetic resonance imaging study. Stroke 48(1):111–116. https://doi.org/10.1161/STROKEAHA.116.014529CrossRefPubMed

26.

Pompsch M, Veltkamp R, Diehl RR, Kraemer M (2022) Microembolic signals and antiplatelet therapy in Moyamoya angiopathy. J Neurol 269(12):6605–6612. https://doi.org/10.1007/s00415-022-11323-4CrossRefPubMed

27.

Kraemer M, Lee SI, Ayzenberg I, Schwitalla JC, Diehl RR, Berlit P, Bosche B, Katsarava Z, Obermann M (2017) Headache in Caucasian patients with Moyamoya angiopathy—a systematic cohort study. Cephalalgia 37(5):496–500. https://doi.org/10.1177/0333102416643516CrossRefPubMed

28.

Ganesan V (2010) Moyamoya: to cut or not to cut is not the only question. A paediatric neurologist’s perspective. Dev Med Child Neurol 52(1):10–13. https://doi.org/10.1111/j.1469-8749.2009.03527.xCrossRefPubMed

29.

Kraemer M, Trakolis L, Platzen J, Schwitalla JC, Bersano A, Albrecht P, Schlamann M, Berlit P (2017) Movement symptoms in European Moyamoya angiopathy—First systematic questionnaire study. Clin Neurol Neurosurg 152:52–56. https://doi.org/10.1016/j.clineuro.2016.11.017CrossRefPubMed

30.

Das S, Ghosh R, Dubey S, Pandit A, Ray BK, Kraemer M (2021) Limb-shaking TIA in Moyamoya angiopathy. Clin Neurol Neurosurg 207:106783. https://doi.org/10.1016/j.clineuro.2021.106783CrossRefPubMed

31.

Das S, Ray BK, Pandit A, Ghosh R, Diehl R, Dubey S, Kraemer M (2022) Profile of precipitating factors and its implication in 160 Indian patients with Moyamoya angiopathy. J Neurol. https://doi.org/10.1007/s00415-022-11499-9CrossRefPubMedPubMedCentral

32.

Nogawa S, Fukuuchi Y, Kobari M, Obara K, Watanabe S, Yamaguchi K, Dembo T (2000) Local zerebral hemodynamic changes through the angiographic stages of moyamoya disease. Keio J Med 49(Suppl 1):A90–A94PubMed

33.

Pilgram-Pastor S, Chapot R, Kraemer M (2022) The angiographic presentation of European Moyamoya angiopathy. J Neurol 269(2):997–1006. https://doi.org/10.1007/s00415-021-10684-6CrossRefPubMed

34.

Uchino H, Ito M, Fujima N, Kazumata K, Yamazaki K, Nakayama N, Kuroda S, Houkin K (2015) A novel application of four-dimensional magnetic resonance angiography using an arterial spin labeling technique for noninvasive diagnosis of Moyamoya disease. Clin Neurol Neurosurg 137:105–111. https://doi.org/10.1016/j.clineuro.2015.07.003CrossRefPubMed

35.

Li J, Jin M, Sun X, Li J, Liu Y, Xi Y, Wang Q, Zhao W, Huang Y (2019) Imaging of Moyamoya disease and Moyamoya syndrome: current status. J Comput Assist Tomogr 43(2):257–263. https://doi.org/10.1097/RCT.0000000000000834CrossRefPubMedPubMedCentral

36.

Kashiwazaki D, Akioka N, Kuwayama N, Houkin K, Czabanka M, Vajkoczy P, Kuroda S (2017) Berlin grading system can stratify the onset and predict perioperative complications in adult Moyamoya disease. Neurosurgery 81(6):986–991. https://doi.org/10.1093/neuros/nyx140CrossRefPubMed

37.

Mertens R, Acker G, Kersting K, Lange C, Furth C, Beyaztas D, Truckenmueller P, Moedl L, Spruenken ED, Czabanka M, Vajkoczy P (2022) Validation of the Berlin Grading System for moyamoya angiopathy with the use of [(15)O]H(2)O PET. Neurosurg Rev 46(1):25. https://doi.org/10.1007/s10143-022-01920-2CrossRefPubMedPubMedCentral

38.

Lu M, Zhang H, Liu D, Hao F, Zhang L, Peng P, Yuan F, Liu S, Sheng F, Liu Y, Zhao X, He Y, Han C, Cai J (2022) Vessel wall enhancement as a predictor of arterial stenosis progression and poor outcomes in moyamoya disease. Eur Radiol. https://doi.org/10.1007/s00330-022-09223-2CrossRefPubMedPubMedCentral

39.

Becker J, Berlit P, Kastrup O, Schuster S, Strunk D, Veltkamp R, Kraemer M (2022) A contrast medium uptake of the vessel wall is not specific for zerebral vasculitis. Nervenarzt 93(12):1271–1273. https://doi.org/10.1007/s00115-022-01304-3CrossRefPubMed

40.

Kraemer M, Strunk D, Becker J, Veltkamp R, Berlit P (2022) Recovery of intracranial stenoses in varicella zoster virus vasculitis after long-term treatment with valacyclovir and prednisolone. Neurol Res Pract 4(1):18. https://doi.org/10.1186/s42466-022-00180-1CrossRefPubMedPubMedCentral

41.

Kraemer M, Berlit P, Diesner F, Khan N (2012) What is the expert’s option on antiplatelet therapy in moyamoya disease? Results of a worldwide Survey. Eur J Neurol 19(1):163–167. https://doi.org/10.1111/j.1468-1331.2011.03481.xCrossRefPubMed

42.

Onozuka D, Hagihara A, Nishimura K, Kada A, Nakagawara J, Ogasawara K, Ono J, Shiokawa Y, Aruga T, Miyachi S, Nagata I, Toyoda K, Matsuda S, Suzuki A, Kataoka H, Nakamura F, Kamitani S, Nishimura A, Kurogi R, Sayama T, Iihara K, Collaborators JAS (2016) Prehospital antiplatelet use and functional status on admission of patients with non-haemorrhagic moyamoya disease: a nationwide retrospective cohort study (J-ASPECT study). BMJ Open 6(3):e9942. https://doi.org/10.1136/bmjopen-2015-009942CrossRefPubMedPubMedCentral

43.

Ye F, Li J, Wang T, Lan K, Li H, Yin H, Guo T, Zhang X, Yang T, Liang J, Wu X, Li Q, Sheng W (2020) Efficacy and safety of antiplatelet agents for adult patients with Ischemic Moyamoya disease. Front Neurol 11:608000. https://doi.org/10.3389/fneur.2020.608000CrossRefPubMed

44.

Seo WK, Kim JY, Choi EH, Kim YS, Chung JW, Saver JL, Bang OY, Kim GM (2021) Association of antiplatelet therapy, including Cilostazol, with improved survival in patients with Moyamoya disease in a nationwide study. J Am Heart Assoc 10(5):e17701. https://doi.org/10.1161/JAHA.120.017701CrossRefPubMedPubMedCentral

45.

Yamada S, Oki K, Itoh Y, Kuroda S, Houkin K, Tominaga T, Miyamoto S, Hashimoto N, Suzuki N, Research Committee on Spontaneous Occlusion of Circle of W (2016) Effects of surgery and antiplatelet therapy in ten-year follow-up from the registry study of research committee on Moyamoya disease in Japan. J Stroke Cerebrovasc Dis 25(2):340–349. https://doi.org/10.1016/j.jstrokecerebrovasdis.2015.10.003CrossRefPubMed

46.

Kuroda S, Houkin K (2012) Bypass surgery for moyamoya disease: concept and essence of sugical techniques. Neurol Med Chir 52(5):287–294. https://doi.org/10.2176/nmc.52.287CrossRef

47.

Araki Y, Uda K, Yokoyama K, Kanamori F, Kurimoto M, Shiba Y, Mamiya T, Nishihori M, Takeuchi K, Tanahashi K, Nagata Y, Nishimura Y, Okamoto S, Sumitomo M, Izumi T, Saito R (2022) Challenging direct bypass surgery for very young children with moyamoya disease: technical notes. Neurosurg Rev 45(2):1799–1807. https://doi.org/10.1007/s10143-021-01685-0CrossRefPubMed

48.

Miyamoto S, Yoshimoto T, Hashimoto N, Okada Y, Tsuji I, Tominaga T, Nakagawara J, Takahashi JC, Investigators JAMT (2014) Effects of extracranial-intracranial bypass for patients with hemorrhagic moyamoya disease: results of the Japan Adult Moyamoya Trial. Stroke 45(5):1415–1421. https://doi.org/10.1161/STROKEAHA.113.004386CrossRefPubMed

49.

Fujimura M, Tominaga T, Kuroda S, Takahashi JC, Endo H, Ogasawara K, Miyamoto S, Research Committee on Moyamoya Disease of the Ministry of Health LWJ, Guideline Committee of the Japan Stroke S (2022) 2021 Japanese guidelines for the management of Moyamoya disease: guidelines from the research committee on Moyamoya disease and Japan stroke society. Neurol Med Chir 62(4):165–170. https://doi.org/10.2176/jns-nmc.2021-0382CrossRef

50.

Lai PMR, Gomez-Paz S, Patel NJ, Frerichs KU, Thomas AJ, Aziz-Sultan MA, Patel AB, Ogilvy CS, Du R (2022) Asymptomatic Moyamoya disease in a north American adult cohort. World Neurosurg 161:e146–e153. https://doi.org/10.1016/j.wneu.2022.01.076CrossRefPubMed

51.

Jeon JP, Kim JE, Cho WS, Bang JS, Son YJ, Oh CW (2018) Meta-analysis of the surgical outcomes of symptomatic moyamoya disease in adults. J Neurosurg 128(3):793–799. https://doi.org/10.3171/2016.11.JNS161688CrossRefPubMed

52.

Baek HJ, Chung SY, Park MS, Kim SM, Park KS, Son HU (2014) Preliminary study of neurocognitive dysfunction in adult moyamoya disease and improvement after superficial temporal artery-middle zerebral artery bypass. J Korean Neurosurg Soc 56(3):188–193. https://doi.org/10.3340/jkns.2014.56.3.188CrossRefPubMedPubMedCentral

53.

Krämer et al (2014) Moyamoya-Erkrankung und Moyamoya-Syndrom. DMV

54.

Bersano A, Khan N, Fuentes B, Acerbi F, Canavero I, Tournier-Lasserve E, Vajcoczy P, Zedde ML, Hussain S, Lémeret S, Kraemer M, Herve D European Stroke Organisation (ESO) Guidelines on Moyamoya angiopathy: Endorsed by Vascular European Reference Network (VASCERN). European Stroke Journal 0 (0):23969873221144089. https://doi.org/10.1177/23969873221144089

55.

Fukui M (1997) Guidelines for the diagnosis and treatment of spontaneous occlusion of the circle of Willis (‘moyamoya’ disease). Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) of the Ministry of Health and Welfare, Japan. Clin Neurol Neurosurg 99(Suppl 2):S238–S240CrossRefPubMed

56.

Research Committee on the P, Treatment of Spontaneous Occlusion of the Circle of W, Health Labour Sciences Research Grant for Research on Measures for Infractable D (2012) Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis). Neurol Med Chir 52(5):245–266. https://doi.org/10.2176/nmc.52.245CrossRef

57.

Herve D, Kossorotoff M, Bresson D, Blauwblomme T, Carneiro M, Touze E, Proust F, Desguerre I, Alamowitch S, Bleton JP, Borsali A, Brissaud E, Brunelle F, Calviere L, Chevignard M, Geffroy-Greco G, Faesch S, Habert MO, De Larocque H, Meyer P, Reyes S, Thines L, Tournier-Lasserve E, Chabriat H (2018) French clinical practice guidelines for Moyamoya angiopathy. Rev Neurol 174(5):292–303. https://doi.org/10.1016/j.neurol.2017.12.002CrossRefPubMed

58.

Hever P, Alamri A, Tolias C (2015) Moyamoya angiopathy—Is there a Western phenotype? Br J Neurosurg 29(6):765–771. https://doi.org/10.3109/02688697.2015.1096902CrossRefPubMed

59.

Grangeon L, Guey S, Schwitalla JC, Bergametti F, Arnould M, Corpechot M, Hadjadj J, Riant F, Aloui C, Drunat S, Vidaud D, Tournier-Lasserve E, Kraemer M (2019) Clinical and molecular features of 5 European multigenerational families with Moyamoya angiopathy. Stroke 50(4):789–796. https://doi.org/10.1161/STROKEAHA.118.023972CrossRefPubMed

60.

Guey S, Grangeon L, Brunelle F, Bergametti F, Amiel J, Lyonnet S, Delaforge A, Arnould M, Desnous B, Bellesme C, Herve D, Schwitalla JC, Kraemer M, Tournier-Lasserve E, Kossorotoff M (2017) De novo mutations in CBL causing early-onset paediatric Moyamoya angiopathy. J Med Genet 54(8):550–557. https://doi.org/10.1136/jmedgenet-2016-104432CrossRefPubMed

61.

Bersano A, Bedini G, Nava S, Acerbi F, Sebastiano DR, Binelli S, Franceschetti S, Farago G, Grisoli M, Gioppo A, Ferroli P, Bruzzone MG, Riva D, Ciceri E, Pantaleoni C, Saletti V, Esposito S, Nardocci N, Zibordi F, Caputi L, Marzoli SB, Zedde ML, Pavanello M, Raso A, Capra V, Pantoni L, Sarti C, Pezzini A, Caria F, Dell’ Acqua ML, Zini A, Baracchini C, Farina F, Sanguigni S, De Lodovici ML, Bono G, Capone F, Di Lazzaro V, Lanfranconi S, Toscano M, Di Piero V, Sacco S, Carolei A, Toni D, Paciaroni M, Caso V, Perrone P, Calloni MV, Romani A, Cenzato M, Fratianni A, Ciusani E, Prontera P, Lasserve ET, Blecharz K, Vajkoczy P, Parati EA, group G-OMs (2019) GEN-O-MA project: an Italian network studying clinical course and pathogenic pathways of moyamoya disease-study protocol and preliminary results. Neurol Sci 40(3):561–570. https://doi.org/10.1007/s10072-018-3664-zCrossRefPubMed

62.

Tho-Calvi SC, Thompson D, Saunders D, Agrawal S, Basu A, Chitre M, Chow G, Gibbon F, Hart A, Tallur KK, Kirkham F, Kneen R, McCullagh H, Mewasingh L, Vassallo G, Vijayakumar K, Wraige E, Yeo TH, Ganesan V, British Paediatric Neurology Association Moyamoya Study g (2018) Clinical features, course, and outcomes of a UK cohort of pediatric moyamoya. Neurology 90(9):e763–e770. https://doi.org/10.1212/WNL.0000000000005026CrossRefPubMed

63.

Hoshino H, Izawa Y, Suzuki N, Research Committee on Moyamoya D (2012) Epidemiological features of moyamoya disease in Japan. Neurol Med Chir 52(5):295–298. https://doi.org/10.2176/nmc.52.295CrossRef

64.

Po C, Nosadini M, Zedde M, Pascarella R, Mirone G, Cicala D, Rosati A, Cosi A, Toldo I, Colombatti R, Martelli P, Iodice A, Accorsi P, Giordano L, Savasta S, Foiadelli T, Sanfilippo G, Lafe E, Thyrion FZ, Polonara G, Campa S, Raviglione F, Scelsa B, Bova SM, Greco F, Cordelli DM, Cirillo L, Toni F, Baro V, Causin F, Frigo AC, Suppiej A, Sainati L, Azzolina D, Agostini M, Cesaroni E, De Carlo L, Di Rosa G, Esposito G, Grazian L, Morini G, Nicita F, Operto FF, Pruna D, Ragazzi P, Rollo M, Spalice A, Striano P, Skabar A, Lanterna LA, Carai A, Marras CE, Manara R, Sartori S (2022) Pediatric Moyamoya disease and syndrome in Italy: a multicenter cohort. Front Pediatr 10:892445. https://doi.org/10.3389/fped.2022.892445CrossRefPubMedPubMedCentral

65.

Birkeland P, Tharmabalan V, Lauritsen J, Ganesan V, Bjarkam CR, von Weitzel-Mudersbach P (2020) Moyamoya disease in a European setting: a Danish population-based study. Eur J Neurol 27(12):2446–2452. https://doi.org/10.1111/ene.14439CrossRefPubMed

66.

Aihara Y, Kashiwase S, Chiba K, Yamaguchi K, Okada Y, Kimura T, Kawamata T (2021) Aspirin use and platelet aggregation in ischemic onset-type pediatric moyamoya patients with intractable headaches (moya-ache). Childs Nerv Syst 37(5):1649–1657. https://doi.org/10.1007/s00381-020-04991-yCrossRefPubMed

67.

Gao B, Kang K, Zhang J, Zhang D, Zhao X (2020) Clinical characteristics and long-term outcome of headaches associated with Moyamoya disease in the Chinese population—A cohort study. Front Neurol 11:605636. https://doi.org/10.3389/fneur.2020.605636CrossRefPubMedPubMedCentral

68.

Henkes H, May A, Kuhne D, Berg-Dammer E, Diener HC (1996) Sumatriptan: vasoactive effect on human dural vessels, demonstrated by subselective angiography. Cephalalgia 16(4):224–230. https://doi.org/10.1046/j.1468-2982.1996.1604224.xCrossRefPubMed

69.

Chiang CC, Shahid AH, Harriott AM, Tietjen GE, Savastano LE, Klaas JP, Lanzino G (2022) Evaluation and treatment of headache associated with moyamoya disease—a narrative review. Cephalalgia 42(6):542–552. https://doi.org/10.1177/03331024211056250CrossRefPubMed

70.

Acker G, Czabanka M, Schmiedek P, Vajkoczy P (2018) Pregnancy and delivery in moyamoya vasculopathy: experience of a single European institution. Neurosurg Rev 41(2):615–619. https://doi.org/10.1007/s10143-017-0901-5CrossRefPubMed

71.

Inayama Y, Kondoh E, Chigusa Y, Io S, Funaki T, Matsumura N, Miyamoto S, Mandai M (2019) Moyamoya disease in pregnancy: a 20-year single-center experience and literature review. World Neurosurg 122:684–691e2. https://doi.org/10.1016/j.wneu.2018.10.071CrossRefPubMed

72.

Fluss R, Ligas BA, Chan AW, Ellis JA, Ortiz RA, Langer DJ, Rahme R (2019) Moyamoya-related stroke risk during pregnancy: an evidence-based reappraisal. World Neurosurg 129:e582–e585. https://doi.org/10.1016/j.wneu.2019.05.225CrossRefPubMed

73.

Haas P, Fudali M, Wang SS, Hurth H, Hauser TK, Ernemann U, Tatagiba M, Khan N, Roder C (2022) Quality of life impairment in adult Moyamoya patients-preoperative neuropsychological assessment and correlation to MRI and H(2)(15)O PET findings. Neurosurg Rev 45(2):1533–1541. https://doi.org/10.1007/s10143-021-01660-9CrossRefPubMed

Titel: Update zu Diagnostik und Therapie der Moyamoya-Angiopathie
Ein White Paper anlässlich der ersten europäischen Leitlinien 2023
verfasst von: Prof. Dr. med. M. Krämer
P. Vajkoczy
N. Khan
Publikationsdatum: 09.05.2023
Verlag: Springer Medizin
Schlagwörter: Apoplex
Apoplex in der Pädiatrie
Operative Therapie des Schlaganfalls
Spontane intrazerebrale Hämatome
Karotisstenose
Arteriovenöse Malformation des Gehirns
Neurologische Diagnostik
Neurologische Therapie
Syndrome und Leitsymptome in der Neurologie
Neurologische Notfälle
Seltene Erkrankungen
Neurologische Notfallmedizin
Karotisstenose
Erschienen in: DGNeurologie / Ausgabe 3/2023
Print ISSN: 2524-3446
Elektronische ISSN: 2524-3454
DOI: https://doi.org/10.1007/s42451-023-00559-7

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2023

Diagnose gesucht: Wiederkehrender Hörverlust und Schwindel

S1-Leitlinie: Therapie und Prophylaxe der Migräne

Magazin

Neue Studie zur spatiotemporalen Verteilung von Remyelinisierungsprozessen bei multipler Sklerose

Kortikosteroide helfen bei Kreuzschmerzen – oder?

Diagnose gesucht – sportliche Frau mit Gangstörung und Marklagerläsionen